{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000031","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.056292+00:00","generated_at":"2026-05-22T11:17:08.205396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Supernus Q1 2025: Qelbree sales +44% to $64.7M; ONAPGO launched; total revenue +4% to $149.8M","bullets":["First quarter 2025 total revenue $149.8M, up 4% YoY; operating loss $(10.3)M vs $(3.2)M in prior year.","Qelbree net sales $64.7M (+44% YoY); GOCOVRI net sales $30.7M (+16% YoY).","ONAPGO (apomorphine infusion) launched in U.S. in April 2025 for Parkinson's motor fluctuations.","Adjusted operating earnings (non-GAAP) increased 16% to $25.9M; full year 2025 guidance reaffirmed.","Qelbree prescriptions grew 22%; March 2025 monthly Rx hit all-time high of 75,277."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000031","json":"https://secwatch.observer/filing/0001356576-25-000031.json","markdown":"https://secwatch.observer/filing/0001356576-25-000031.md","text":"https://secwatch.observer/filing/0001356576-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000031/0001356576-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000031/supn-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:17:08.205396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}